Mostrar el registro sencillo del ítem
dc.contributor.author
Ayala, Natalia Carolina
dc.contributor.author
Alsina, Angel Esteban
dc.contributor.author
Gomez Pescie, Mariana
dc.contributor.author
Lerzo, Guillermo Luis
dc.contributor.author
Zimerman, Jorge Raul
dc.contributor.author
Zimmermann, Maria Carla
dc.date.available
2023-02-03T16:51:15Z
dc.date.issued
2016
dc.identifier.citation
CXCR4/SDF1 expression in HER2/neu breast cancer biopsies and its relation to adjuvant treatment; Annual Meeting American Society of Clinical Oncology; Chicago, IL; Estados Unidos; 2016; 1-2
dc.identifier.uri
http://hdl.handle.net/11336/186813
dc.description.abstract
Background: Chemokines have a fundamental role in inflammation and in cancer progression. Chemokine receptor 4 (CXCR4) is a transmembrane receptor that belongs to the CXC chemokine receptor family and is the only known receptor for the Stromal Cell derived Factor1(SDF1). Many retrospective studies have documented that the expression of various chemokine receptors, particularly CXCR4, was associated with a poor prognosis in patients with breast cancer. In the present study, we proposed an SDF1/CXCR4 induced expression in HER2/neu positive breast cancer biopsies. We, additionally, study its relation to patient’s treatment, prior and post adjuvant therapy. Methods: Immunohistochemical staining of her2/neu and ki64 were analyzed in mammary tumor biopsies. Reduction mammoplasty of normal patients were also studied as normal controls. Stained hematoxilyn and eosin slides where previously revised to confirm histological diagnostic and tumoral classification based on established criteria. Additional information considering biological markers such as estrogen receptor (ER), progesterone receptor (PR) expression were also observed in histopathological reports. Quantitative PCR was performed by amplifying a conserved region of the CXCR4 and SDF1 genes, and their correlation to Her2/neu expression and adjuvant therapy were analyzed. Statistical analysis was assess using appropriate parametric and nonparametric tests. Results: Her2/neu breast tumor specimens expressed SDF1 at varying levels and differed upon tumor classification. Expression of the receptor correlates mainly with the tumor type and degree. Quantitative PCR showed low constitutive CXCR4 expression in normal breast tissue that increased in breast tumor tissue, particularly in those expressing her2/neu. Variations upon treatment correspond to those of tumor progression to malignancies and recurrence. Conclusions: We established a correlation between the expression of SDF1/CXCR4 and the tumoral characteristics prior and post adjuvant treatment. A more careful examination of experimental/clinical data may help to explain the mechanism(s) involving the SDF1/CXCR4 signaling axis in the breast cancer pathophysiology.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
American Society of Clinical Oncology
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
CXCR4/SDF1
dc.subject
HER2/neu
dc.subject
Breast Cancer
dc.subject
Adjuvant Treatment
dc.subject.classification
Oncología
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
CXCR4/SDF1 expression in HER2/neu breast cancer biopsies and its relation to adjuvant treatment
dc.type
info:eu-repo/semantics/publishedVersion
dc.type
info:eu-repo/semantics/conferenceObject
dc.type
info:ar-repo/semantics/documento de conferencia
dc.date.updated
2022-12-22T10:07:53Z
dc.journal.volume
34
dc.journal.number
15
dc.journal.pagination
1-2
dc.journal.pais
Estados Unidos
dc.journal.ciudad
Alexandria
dc.description.fil
Fil: Ayala, Natalia Carolina. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina
dc.description.fil
Fil: Alsina, Angel Esteban. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina
dc.description.fil
Fil: Gomez Pescie, Mariana. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina
dc.description.fil
Fil: Lerzo, Guillermo Luis. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina
dc.description.fil
Fil: Zimerman, Jorge Raul. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina
dc.description.fil
Fil: Zimmermann, Maria Carla. Universidad Nacional del Nordeste. Facultad de Medicina. Cátedra de Farmacología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; Argentina
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.e12090
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://meetinglibrary.asco.org/browse-meetings/2016%20ASCO%20Annual%20Meeting
dc.conicet.rol
Autor
dc.conicet.rol
Autor
dc.conicet.rol
Autor
dc.conicet.rol
Autor
dc.conicet.rol
Autor
dc.conicet.rol
Autor
dc.coverage
Internacional
dc.type.subtype
Reunión
dc.description.nombreEvento
Annual Meeting American Society of Clinical Oncology
dc.date.evento
2016-06-03
dc.description.ciudadEvento
Chicago, IL
dc.description.paisEvento
Estados Unidos
dc.type.publicacion
Journal
dc.description.institucionOrganizadora
American Society for Clinical Oncology
dc.source.revista
Journal Of Clinical Oncology
dc.date.eventoHasta
2016-06-07
dc.type
Reunión
Archivos asociados